ANTIBODY SHOP

Services
Name:
Phone:
E-mail:
Message

RD | N-terminal arginylation

420 €

AS15 3050A | Clonality: Polyclonal | Host: Rabbit | Reactivity: RD | N-terminal arginylation

PRODUCT INFORMATION IN PDF

Qty: 
Availability:
11 st
Delivery:
Shipping:
Item No:
AS15 3050A

Info: More information Product suggestions Add review
product information
Background Arginylation is a post-translational modification of an existing peptide chain by addition of an extra arginine. This modification changes primary sequence of protein as well as it's surface change. It is mediated by arginyltransferase ATE1. Arginylation plays an essential role in multiple physiological pathways, for example, in vivo arginylation constitutes a mechanism for degradation of preprocessed proteins or proteolytic fragments that bear Asp and Glu on their N-termini.
Immunogen

KLH-conjugated synthetic peptide: H-RDHKHANQHMSVC-NH2

Host Rabbit
Clonality Polyclonal
Clone
Purity Affinity purified serum in PBS pH 7.4
Format
Quantity 2 x 25 µg
Reconstitution

For reconstitution add 25 ĩl of sterile water to each tube.

Storage

Store lyophilized/reconstituted at -20°C; once reconstituted make aliquots to avoid repeated freeze-thaw cycles. Please, remember to spin tubes briefly prior to opening them to avoid any losses that might occur from lyophilized material adhering to the cap or sides of the tubes.

Tested applications

Dot blot (Dot)

Related products

AS15 3050 | anti-RE | N-terminal arginylation, rabbit antibodies

collection of antibodies to proteins involved in transcription
collection of antibodies to proteins involved in translation

Plant protein extraction buffer

Secondary antibodies

Additional information Antibodies are purified using substactive purification method.

MG132 or epoxomycin are recommended to use to inhibit proteasome and significantly increase signal from the arginylated proteins.
application information
Recommended dilution

1 : 1000 (Dot)

Expected | apparent MW
Confirmed reactivity
Predicted reactivity
Not reactive in
Additional information
Selected references

To be added when available, antibody released in June 2016.


Application information

Dot blot using anti-arginylation antibodies


  • Membrane: PVDF, Hybond 0.45 μm (GE Healthcare)
  • 0.5 µg synthetic peptide per spot
  • Membrane was blocked overnight in TBST, 4% Blocking Agent (GE Healthcare)
  • Primary antibodies: 1:10 000 in TBST 2% Blocking Agent
  • Secondary antibody (AS09 602): 1:25 000 in TBST 2% Blocking Agent
  • Detection: ECL Advance (GE Healthcare)


Courtesy of Dr. Sebastian Hoernstein, Faculty of Biology, University of Freiburg; Germany